Neoplasms

All Conditions

Digestive System Diseases

Adenocarcinoma

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

regorafenib

Regorafenib as a Second Line Single Agent in the Treatment of Metastatic or Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach

Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers

Patients had disease assessed by CT scans. Stable Disease is defined by any response better than Progression as defined by RECIST 1.1. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

University of Utah

Regorafenib Treatment

Age, Categorical

Sex: Female, Male

United States

Region of Enrollment

Kimberlee Taylor

3 subjects did not complete an 8 week EOT visit for: Death, Patient W/D, AE.

Number of Participants With Stable Disease at Eight Weeks Post-Treatment

160 mg regorafenib by mouth once daily for 3 weeks of every 4 week cycle

Overall Study

Spots Global Cancer Trial Database for Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial